作者
LV Sequist, RS Heist, AT Shaw, P Fidias, R Rosovsky, JS Temel, IT Lennes, S Digumarthy, BA Waltman, E Bast, S Tammireddy, L Morrissey, A Muzikansky, SB Goldberg, J Gainor, CL Channick, JC Wain, H Gaissert, DM Donahue, A Muniappan, C Wright, H Willers, DJ Mathisen, NC Choi, J Baselga, TJ Lynch, LW Ellisen, M Mino-Kenudson, M Lanuti, DR Borger, AJ Iafrate, JA Engelman, D Dias-Santagata
发表日期
2011/12/1
期刊
Annals of Oncology
卷号
22
期号
12
页码范围
2616-2624
出版商
Elsevier
简介
Background
Personalizing non-small-cell lung cancer (NSCLC) therapy toward oncogene addicted pathway inhibition is effective. Hence, the ability to determine a more comprehensive genotype for each case is becoming essential to optimal cancer care.
Methods
We developed a multiplexed PCR-based assay (SNaPshot) to simultaneously identify >50 mutations in several key NSCLC genes. SNaPshot and FISH for ALK translocations were integrated into routine practice as Clinical Laboratory Improvement Amendments-certified tests. Here, we present analyses of the first 589 patients referred for genotyping.
Results
Pathologic prescreening identified 552 (95%) tumors with sufficient tissue for SNaPshot; 51% had ≥1 mutation identified, most commonly in KRAS (24%), EGFR (13%), PIK3CA (4%) and translocations involving ALK (5%). Unanticipated mutations were observed at lower frequencies in IDH and β …
学术搜索中的文章
LV Sequist, RS Heist, AT Shaw, P Fidias, R Rosovsky… - Annals of Oncology, 2011